GenBio Inc.

The manufacturing process was novel in removing the inherent oils, thus concentrating the antioxidant polyphenol classes of bioactive compounds.

ALISO VIEJO, CA, UNITED STATES, August 17, 2022 /EINPresswire.com/ -- GenBio Inc. has just completed its first phase research into a more refined indigenous Australian extract, the first of its kind. The manufacturing process was novel in removing the inherent oils, thus concentrating the antioxidant polyphenol classes of bioactive compounds. It is envisaged that this extract with potentially increased potency will remain in the herbal/dietary classification of food grade products, enabling entirely new ranges of nutraceutical products to be designed for even more effective immune support and improved overall human health. The unique extract is now undergoing further specialized high resolution chromatographic and biochemical research to define the individual compounds and their specific mechanisms of action for health support.

Emphasis will be placed on those mechanisms that will improve the handling of dietary fats in the body, especially normalizing the diet-induced changes in the gut microbiome, improving the handling of fats by the liver, and reversing changes in fat transport in the blood. This multi-pronged attack will allow lower doses of the extract to reduce the symptoms of chronic human disease.

About GenBio, Inc.
GenBio, Inc. (https://genbioinc.com/) aims to create, through its IND Drug program, the next generation of anti-inflammatory drugs with the intention to disrupt the projected $191 billion+ anti-inflammatory drug market. GenBio, in addition, has access to a vast catalog of natural herbs, extracts, superfoods and functional food ingredients that can and will be formulated and licensed out to create a range of new nutraceuticals to aid in boosting the human immune system and promoting good health and longevity.

Forward Looking Statements
Statements in this press release about the future expectations, including without limitation, the likelihood that GenBio, Inc. will be able to meet minimum expectations, be successful and leverage capital markets to execute its growth strategy, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unexpected events, except as required by law. GenBio’s business strategy described in this press release is subject to innumerable risks, most significantly, whether the Company is successful in securing adequate financing. No information in this press release should be construed in any form, shape, or manner as an indication of the Company’s future revenues or financial condition.
Contact:

Todd D. Sonoga
GenBio Inc.
+1 949-705-8021
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.